ProtoKinetix, Incorporated (PKTX)
ProtoKinetix, Incorporated operates in the Biotechnology industry of the Healthcare sector, headquartered in Dalton, OH, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $156,632. On trailing twelve-month figures it carries a trailing P/E of -0.67, a net margin of 0.0%. Its beta of 0.73 implies it has historically moved less than the broad market.
ProtoKinetix, Incorporated is a biotechnology firm engaged in research and development, specializing in the scientific and medical investigation of glycoproteins known as anti-freeze glycoproteins (AFGPs) and anti-aging glycoproteins (AAGPs). These AFGPs are particularly relevant for their commercial potential within the healthcare sector, with a key area of their development involving utilizing AAGPs for the treatment of dry-eye conditions. Their research efforts are bolstered by a collaborative agreement with the University of British Columbia. Originally incorporated in 1999 as RJV Network, Inc., the company adopted its current name, ProtoKinetix, Incorporated, in July 2003. Its operational headquarters are situated in Marietta, Ohio.
ProtoKinetix, Incorporated is most often compared with the following Healthcare names: